Phase 2 investigator-initiated, multi-center, unblinded, non-comparative trial of Opdivo in naïve or previously chemotherapy-treated patients with malignant mesothelioma (excluding malignant pleural mesothelioma)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab (Primary)
Indications Mesothelioma
Focus Therapeutic Use
Acronyms VIOLA

Most Recent Events

24 Nov 2023 Primary endpoint (Objective response rate (Central Judgment).) has been met as per results published in the Ono Pharmaceutical Media Release
24 Nov 2023 Results published in the Ono Pharmaceutical Media Release
24 Nov 2023 According to a Ono Pharmaceutical media release, based upon this trial, ONO has received supplemental approval of Opdivo (generic name: nivolumab) Intravenous Infusion for expanded use for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight